G1 Therapeutics, Inc.

NasdaqGS:GTHX 株式レポート

時価総額：US$132.3m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

G1 Therapeutics マネジメント

マネジメント 基準チェック /24

G1 Therapeutics'の CEO はJack Baileyで、 Jan2021年に任命され、 の在任期間は 3.42年です。 の年間総報酬は$ 3.25Mで、 24.5%給与と75.5%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.36%を直接所有しており、その価値は$ 481.56K 。経営陣と取締役会の平均在任期間はそれぞれ3.4年と5.8年です。

主要情報

Jack Bailey

最高経営責任者

US$3.3m

報酬総額

CEO給与比率24.5%
CEO在任期間3.4yrs
CEOの所有権0.4%
経営陣の平均在職期間3.4yrs
取締役会の平均在任期間5.8yrs

経営陣の近況

Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why

Jun 07
Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why

Recent updates

Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why

Jun 07
Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

May 28
Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 04
G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape

Mar 22

Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge

Feb 27
Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge

Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

Feb 06
Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry

Jan 04
G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

Jun 08
Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)

May 08
New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)

The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts

Nov 04
The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts

G1 Therapeutics: Catalysts Stacking

Oct 20

G1 Therapeutics: Building A Franchise

Sep 29

Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)

Aug 04
Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)

G1 Therapeutics Q2 2022 Earnings Preview

Aug 02

G1 Therapeutics: Take Advantage Of The November Data

Jul 22

G1 Therapeutics granted regulatory nod for cancer therapy in China

Jul 13

G1 Therapeutics: Needs To Expand Labels And Commercialize Better

Apr 27

Health Check: How Prudently Does G1 Therapeutics (NASDAQ:GTHX) Use Debt?

Apr 19
Health Check: How Prudently Does G1 Therapeutics (NASDAQ:GTHX) Use Debt?

G1 Therapeutics: Biotech With FDA Approved Drug Plus Additional Potential

Feb 08

G1 Therapeutics (NASDAQ:GTHX) Has Debt But No Earnings; Should You Worry?

Dec 07
G1 Therapeutics (NASDAQ:GTHX) Has Debt But No Earnings; Should You Worry?

CEO報酬分析

G1 Therapeutics の収益と比較して、Jack Bailey の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2024n/an/a

-US$31m

Dec 31 2023US$3mUS$795k

-US$48m

Sep 30 2023n/an/a

-US$71m

Jun 30 2023n/an/a

-US$78m

Mar 31 2023n/an/a

-US$126m

Dec 31 2022US$3mUS$764k

-US$148m

Sep 30 2022n/an/a

-US$154m

Jun 30 2022n/an/a

-US$171m

Mar 31 2022n/an/a

-US$171m

Dec 31 2021US$9mUS$735k

-US$148m

Sep 30 2021n/an/a

-US$134m

Jun 30 2021n/an/a

-US$103m

Mar 31 2021n/an/a

-US$95m

Dec 31 2020US$2mn/a

-US$99m

報酬と市場: Jackの 総報酬 ($USD 3.25M ) は、 US市場 ($USD 678.50K ) の同規模の企業の平均を上回っています。

報酬と収益: Jackの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Jack Bailey (59 yo)

3.4yrs

在職期間

US$3,250,658

報酬

Mr. John E. Bailey, also known as Jack, Jr. has been Director at G1 Therapeutics, Inc. since March 12, 2020. He serves as President and Chief Executive Officer at G1 Therapeutics Inc. since January 1, 2021...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
John Bailey
CEO, President & Director3.4yrsUS$3.25m0.36%
$ 475.9k
Rajesh Malik
Chief Medical Officer9.9yrsUS$1.11m0.16%
$ 214.6k
Mark Avagliano
Chief Business Officer4.9yrsUS$1.17m0.044%
$ 58.8k
John Umstead
Chief Financial Officer1.3yrsデータなし0.036%
$ 47.5k
Terry Murdock
Chief Operating Officer5.4yrsUS$2.75m0.035%
$ 46.8k
William Roberts
Vice President of Investor Relations & Corporate Communications3.4yrsデータなしデータなし
Monica Thomas
Chief Legal & People Officer1.1yrsデータなし0.013%
$ 17.3k
Evan Hicks
Vice President of Marketingno dataデータなしデータなし
Andrew Perry
Chief Commercial Officer2.8yrsUS$3.39m0.024%
$ 32.4k
Jeff Macdonald
Senior Director of Investor Relations & Corporate Communicationsno dataデータなしデータなし

3.4yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: GTHXの経営陣は 経験豊富 であると考えられます ( 3.4年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
John Bailey
CEO, President & Director4.3yrsUS$3.25m0.36%
$ 475.9k
Seth Rudnick
Member of Clinical Advisory Boardno dataUS$456.29kデータなし
Glenn Muir
Independent Director8.8yrsUS$172.85k0.35%
$ 469.0k
Joseph Bailes
Scientific & Clinical Advisorno dataデータなしデータなし
George Demetri
Scientific & Clinical Advisorno dataデータなしデータなし
Cynthia Flowers
Independent Director6yrsUS$162.85k0.030%
$ 40.2k
Garry Nicholson
Independent Chairman of the Board5.8yrsUS$195.35k0.028%
$ 36.4k
Gary Lyman
Scientific & Clinical Advisorno dataデータなしデータなし
Norman Sharpless
Director1.9yrsUS$135.35k0%
$ 0
Kwok-Kin Wong
Co-Founder & Member of Scientific Advisory Boardno dataデータなしデータなし
Donald McDonnell
Scientific & Clinical Advisorno dataデータなしデータなし
Geoffrey Shapiro
Scientific & Clinical Advisorno dataデータなしデータなし

5.8yrs

平均在職期間

67yo

平均年齢

経験豊富なボード: GTHXの 取締役会 は 経験豊富 であると考えられます ( 5.8年の平均在任期間)。